PeptideStack
5.2kquestions
20kanswers
220users

Is there any published stability data for a GLP-1 receptor agonist at room temperature?

Asked 5 Oct 2024Modified 18 months agoViewed 13k times
9

What I have: a GLP-1 receptor agonist · room temperature.

I would rather be corrected now than propagate something wrong.

I am specifically not interested in a testimonial; I am interested in a measurement.

Is this actually true, and what is the evidence?

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
shareeditfollowflag
SW
askedswab_and_wait13k165 Oct 2024
7Do you know the residual moisture? It predicts this better than any date does. – Dr_Bram_Verhoeven 2 months ago
add a comment

2 Answers

Sorted by votes
20

room temperature is one of the two points formal stability programmes actually run, so this is the rare case where the literature is looking where you are. Accelerated work is conventionally run at 25 °C and 40 °C, with the refrigerated condition as the control. Room temperature is not a number, so take the pharmacopoeial 20–25 °C and its 22.5 °C midpoint: 17.5 kelvin above the 5 °C middle of a 2–8 °C refrigerator. The ten-degree rule of thumb — degradation rate roughly doubling per 10 K — puts that at about 3.4 times the refrigerated rate. It is an order-of-magnitude statement about a rate, not a shelf life, and the top of the 20–25 °C band runs about 1.4 times faster than the bottom of it. Whatever you find, check what was measured before you use it: a paper reporting purity at room temperature has not measured content, and the two fail at different rates for different reasons.

Answer first: the degradation pathways worth knowing are hydrolysis, deamidation, oxidation, aggregation and adsorption, and each has a different trigger and a different mitigation.

Deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.

Hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.

At dilute concentrations, suspect adsorption before you suspect chemistry.

edited 20 Oct 2024 by marta_okonkwo — clarified the distinction between purity and content

shareimprove this answerflag
MO
answeredmarta_okonkwo190k2589 Oct 2024
8Adding for future readers: the domestic leg after delivery is the part you control. – Dr_Otto_Lindqvist 9 months ago
add a comment
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards
14

The short version: water enables most of it, oxygen enables oxidation, surfaces enable adsorption, and agitation enables aggregation.

Light exposure matters for tryptophan-containing sequences and for anything with a chromophore. Amber vials and a closed box are free mitigations.

A mass spectrum resolves most of this: minus eighteen is dehydration or succinimide, plus one is deamidation, plus sixteen is oxidation, and an unchanged mass with a shifted retention time is an isomer.

Deamidation via the succinimide intermediate is well characterised, with sequence-dependent rates highest for asparagine-glycine motifs.

Swirl, never shake. Aggregation is a handling problem more than a time problem.

shareimprove this answerflag
TH
answeredtyndall_haze38k3826 Jan 2025
8Confirming that opening a cold vial in a humid room is a genuinely bad idea. – mz_4113 8 months ago
7This should be linked from the help pages. – dead_volume 6 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.